2023 Q2 Form 10-Q Financial Statement

#000164033423000968 Filed on May 26, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change
Cash & Equivalents $0.00 $0.00
Short-Term Investments
Other Short-Term Assets $500.00
YoY Change
Inventory
Prepaid Expenses $500.00
Receivables
Other Receivables
Total Short-Term Assets $500.00 $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $500.00 $0.00
Total Long-Term Assets $0.00 $0.00
Total Assets $500.00 $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.60K $10.00K
YoY Change 96.0% -0.1%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $90.52K $60.03K
YoY Change 50.79% 95.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $90.52K $60.03K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $90.52K $60.03K
YoY Change 50.79% 95.18%
SHAREHOLDERS EQUITY
Retained Earnings -$379.1K -$349.1K
YoY Change 8.59% 9.15%
Common Stock $31.52K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$90.02K -$60.03K
YoY Change
Total Liabilities & Shareholders Equity $500.00 $0.00
YoY Change

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
19600 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9800 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
90522 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-90022 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
500 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q1 us-gaap Cash
Cash
0 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1250 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
500 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1250 usd
CY2023Q1 us-gaap Assets
Assets
500 usd
CY2022Q4 us-gaap Liabilities
Liabilities
80722 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
31518 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
31518 usd
CY2022Q4 us-gaap Assets
Assets
1250 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
257587 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-368577 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-79472 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1250 usd
CY2022Q1 us-gaap Revenues
Revenues
0 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
9725 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
0 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
9725 usd
CY2022Q1 huaizhong Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.0003
CY2022Q1 huaizhong Basic And Diluted Weighted Average Common Shares Outstanding
BasicAndDilutedWeightedAverageCommonSharesOutstanding
31518466 shares
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
9800 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
750 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
10550 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10550 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001593204
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31518466 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31518466 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31518466 shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-01-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-55369
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
HUAIZHONG HEALTH GROUP, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1020141
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Tianan Technology Park
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
13/F Headquarters Center Building 16
CY2023Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
555 Panyu North Ave, Panyu District
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Guangzhou City
CY2023Q1 dei Entity Address Country
EntityAddressCountry
CN
CY2023Q1 dei City Area Code
CityAreaCode
86 (20)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
2982 9356
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31518466 shares
CY2022Q4 us-gaap Cash
Cash
0 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
500 usd
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
70922 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
70922 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
80722 usd
CY2023Q1 us-gaap Liabilities
Liabilities
90522 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31518466 shares
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
257587 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-379127 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9725 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10550 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9725 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10550 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9725 usd
CY2023Q1 huaizhong Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.0003
CY2023Q1 huaizhong Basic And Diluted Weighted Average Common Shares Outstanding
BasicAndDilutedWeightedAverageCommonSharesOutstanding
31518466 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-79472 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10550 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-90022 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-50301 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9725 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-60026 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10550 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9725 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
750 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9800 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
50 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9675 usd
CY2023Q1 huaizhong Proceeds From Related Party Advances Funding Operations
ProceedsFromRelatedPartyAdvancesFundingOperations
0 usd
CY2022Q1 huaizhong Proceeds From Related Party Advances Funding Operations
ProceedsFromRelatedPartyAdvancesFundingOperations
9675 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9675 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p>
CY2023Q1 huaizhong Reclassification Policy Textblock
ReclassificationPolicyTextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain accounts from prior periods have been reclassified to conform to the current period presentation.</p>
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-379127 usd

Files In Submission

Name View Source Status
0001640334-23-000968-index-headers.html Edgar Link pending
0001640334-23-000968-index.html Edgar Link pending
0001640334-23-000968.txt Edgar Link pending
0001640334-23-000968-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
huaizhong-20230131.xsd Edgar Link pending
huaizhong_10q.htm Edgar Link pending
huaizhong_ex311.htm Edgar Link pending
huaizhong_ex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
huaizhong-20230131_def.xml Edgar Link unprocessable
huaizhong-20230131_cal.xml Edgar Link unprocessable
huaizhong-20230131_pre.xml Edgar Link unprocessable
huaizhong-20230131_lab.xml Edgar Link unprocessable
huaizhong_10q_htm.xml Edgar Link completed